Tracking rabies vaccines for pre-exposure prophylaxis and post-exposure treatment. Rabies is 99.9% fatal once symptoms appear but nearly 100% preventable with prompt post-exposure vaccination. Licensed vaccines (Verorab, Imovax Rabies, RabAvert) save thousands of lives annually. Globally, ~59,000 deaths occur yearly, mostly in Asia and Africa from dog bites. This tracker monitors licensed vaccines, next-generation candidates for simplified dosing, intradermal administration, and rabies immunoglobulin alternatives. WHO goal: Zero human rabies deaths by 2030 through mass dog vaccination and improved human post-exposure prophylaxis access.
Rabies is almost universally fatal once symptoms appear, but nearly 100% preventable with prompt post-exposure prophylaxis (PEP). ~59,000 deaths annually, 95% in Asia/Africa. Children under 15 account for 40% of deaths.
WHO, FAO, WOAH, and the Global Alliance for Rabies Control (United Against Rabies) are pursuing the "Zero by 30" goal: zero human deaths from dog-mediated rabies by 2030. Progress hinges on three pillars — (1) mass dog vaccination to interrupt canine transmission, (2) timely and complete post-exposure prophylaxis for exposed people, and (3) community education. Gavi's Vaccine Investment Strategy 2021–2025 added human rabies vaccine for the first time, funding scale-up in eligible countries. WHO 2018 and updated 2024 guidance now recommend rabies monoclonal antibodies (mAbs) as an alternative to human/equine rabies immunoglobulin for wound infiltration in Category III exposures. India has already licensed two mAb products for domestic use. mAbs offer standardized potency, scalable production, and lower cost (~$30–50/treatment vs. $300–3,000 for RIG) — potentially removing the biggest bottleneck in PEP access in low-income settings.
📊 View all rabies vaccine trials on ClinicalTrials.gov →
🌍 CDC Rabies Information →
🌍 WHO Rabies Resources →
🌍 Global Alliance for Rabies Control →
📰 Latest Rabies Vaccine News (Google News) →